Brokerages Anticipate Atara Biotherapeutics Inc (NASDAQ:ATRA) to Post -$1.29 Earnings Per Share

Wall Street brokerages forecast that Atara Biotherapeutics Inc (NASDAQ:ATRA) will report earnings per share of ($1.29) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Atara Biotherapeutics’ earnings. The lowest EPS estimate is ($1.32) and the highest is ($1.27). Atara Biotherapeutics reported earnings of ($1.75) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 26.3%. The business is expected to issue its next quarterly earnings report on Tuesday, February 25th.

According to Zacks, analysts expect that Atara Biotherapeutics will report full year earnings of ($5.45) per share for the current fiscal year, with EPS estimates ranging from ($5.63) to ($5.14). For the next financial year, analysts anticipate that the firm will report earnings of ($4.76) per share, with EPS estimates ranging from ($5.60) to ($3.09). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Atara Biotherapeutics.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($1.31) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.40) by $0.09.

ATRA has been the topic of several analyst reports. ValuEngine raised shares of Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd. Stifel Nicolaus restated a “buy” rating on shares of Atara Biotherapeutics in a report on Friday, October 25th. JPMorgan Chase & Co. cut Atara Biotherapeutics from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $43.00 to $22.00 in a report on Friday, November 8th. BidaskClub raised Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, January 8th. Finally, Cowen reiterated a “buy” rating on shares of Atara Biotherapeutics in a report on Tuesday, December 10th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $28.22.

Atara Biotherapeutics stock opened at $16.80 on Wednesday. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.05. Atara Biotherapeutics has a 1-year low of $10.38 and a 1-year high of $41.97. The company has a fifty day simple moving average of $15.53 and a 200 day simple moving average of $14.65. The company has a market cap of $894.57 million, a P/E ratio of -3.19 and a beta of 2.07.

A number of hedge funds and other institutional investors have recently bought and sold shares of ATRA. Maverick Capital Ltd. grew its position in shares of Atara Biotherapeutics by 128.6% in the 3rd quarter. Maverick Capital Ltd. now owns 5,103,963 shares of the biotechnology company’s stock valued at $72,068,000 after acquiring an additional 2,871,487 shares during the period. Metropolitan Life Insurance Co NY raised its holdings in shares of Atara Biotherapeutics by 17.3% in the 3rd quarter. Metropolitan Life Insurance Co NY now owns 15,648 shares of the biotechnology company’s stock valued at $221,000 after purchasing an additional 2,307 shares during the period. Squarepoint Ops LLC acquired a new stake in Atara Biotherapeutics in the 3rd quarter valued at about $352,000. Great Point Partners LLC acquired a new stake in Atara Biotherapeutics in the 3rd quarter valued at about $7,060,000. Finally, California State Teachers Retirement System grew its holdings in Atara Biotherapeutics by 17.5% during the third quarter. California State Teachers Retirement System now owns 80,227 shares of the biotechnology company’s stock worth $1,133,000 after purchasing an additional 11,924 shares during the period.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Recommended Story: What member countries make up the G-20?

Get a free copy of the Zacks research report on Atara Biotherapeutics (ATRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.